Table 1. Baseline characteristics of patients with PTE who received alteplase 100 mg.
| Characteristics | Total (n = 38) | Non-bleeding (n = 22) | Minor bleeding (n = 6) | Major bleeding (n = 10) | P value | |
|---|---|---|---|---|---|---|
| Men | 18 (47.4) | 13 (59.1) | 2 (33.3) | 3 (30) | 0.321 | |
| Age, yr | 70.68 ± 13.15 | 70.86 ± 15.78 | 66.50 ± 7.26 | 72.80 ± 9.15 | 0.659 | |
| < 65 | 8 (21.0) | 6 (27.3) | 1 (16.7) | 1 (10.0) | ||
| 65–75 | 14 (36.8) | 6 (27.3) | 4 (67.7) | 4 (40.0) | ||
| ≥ 75 | 16 (42.1) | 10 (45.5) | 1 (16.7) | 5 (50.0) | ||
| Body weight, kg | 63.55 ± 12.09 | 62.24 ± 14.62 | 63.97 ± 12.10 | 66.17 ± 5.38 | 0.819 | |
| < 50 | 3 | 3 | 0 | 0 | ||
| ≥ 50 | 19 | 10 | 3 | 6 | ||
| BMI, kg/m2 | 23.83 ± 4.04 | 23.00 ± 4.87 | 23.90 ± 1.86 | 23.83 ± 4.04 | 0.448 | |
| < 18.5 | 2 | 2 | 0 | 0 | ||
| 18.5–25 | 10 | 6 | 2 | 2 | ||
| ≥ 25 | 10 | 5 | 1 | 4 | ||
| SOFA score | 6.24 ± 4.39 | 8.27 ± 4.53 | 2.00 ± 0.00 | 3.71 ± 1.60 | 0.009 | |
| Risk of PTE | ||||||
| High | 34 (89.5) | 20 (91.0) | 4 (66.7) | 10 (100.0) | ||
| Intermediate | 4 (10.5) | 2 (9.0) | 2 (33.3) | 0 (0) | ||
| Previous disease | ||||||
| Hypertension | 20 (52.6) | 13 (59.1) | 1 (16.7) | 6 (60.0) | 0.189 | |
| Diabetes | 7 (18.4) | 3 (13.6) | 0 (0) | 4 (40.0) | 0.139 | |
| Cardiovascular disease | 15 (39.5) | 7 (31.8) | 1 (16.7) | 7 (70.0) | 0.081 | |
| Pulmonary disease | 4 (10.5) | 2 (9.1) | 1 (16.7) | 1 (10.0) | 0.791 | |
| Renal disease | 5 (13.2) | 2 (9.1) | 0 (0) | 3 (30.0) | 0.251 | |
| Malignancy | 6 (15.8) | 4 (18.2) | 0 (0) | 2 (20.0) | 0.690 | |
| Use of anticoagulation & antiplatelet agent | ||||||
| Aspirin | 10 (26.3) | 5 (22.7) | 0 (0) | 5 (50.0) | 0.119 | |
| P2Y12 inhibitor | 2 (5.3) | 2 (9.1) | 0 (0) | 0 (0) | 0.687 | |
| Anticoagulant | 3 (7.9) | 3 (13.6) | 0 (0) | 0 (0) | 0.726 | |
Data are presented as mean ± standard deviation or number (%).
PTE = pulmonary thromboembolism, BMI = body mass index, SOFA score = sequential organ failure assessment score.